Call for Abstract
Scientific Program
19th International Conference on Medicinal Chemistry & Multi Targeted Drug Delivery, will be organized around the theme “Scientific Novelty and Advanced Perception in Medicinal Chemistry”
MedChem & MTDD 2018 is comprised of 43 tracks and 182 sessions designed to offer comprehensive sessions that address current issues in MedChem & MTDD 2018.
Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.
Register now for the conference by choosing an appropriate package suitable to you.
- Track 1-1 Target discovery and validation
- Track 1-2Molecular modelling
- Track 1-3Drug receptor interactions
- Track 1-4Pro drug synthesis and drug targeting
- Track 1-5Toxicity, and therapeutic applications of antibiotics, antifungals, and antivirals
- Track 2-1Drug-Receptor Interactions
- Track 2-2The Biological Evaluation of New Compounds
- Track 2-3 Pharmacokinetics
- Track 2-4Drug Metabolism
- Track 2-5Physicochemical Properties and Drug Design
- Track 2-6Considerations for the Use of Computational Chemistry Techniques by Medicinal Chemists
- Track 2-7Organic synthesis of ligands and inhibitors
- Track 2-8Protein biochemistry.
- Track 2-9Development of screening and assay methods
- Track 2-10Molecular biology and genetic engineering
- Track 3-1Research Strategies
- Track 3-2Methodologies and literature concerning the mechanisms of drug action and drug metabolism
- Track 4-1BACE Inhibitors
- Track 4-2Passive Immunotherapy
- Track 4-3Enhancing Cognition
- Track 4-4Anti-Amyloid Treatment
- Track 4-5Targets for future drugs
- Track 5-1Biochemical mechanisms for the biotransformation of drugs and foreign compounds
- Track 5-2Reaction mechanisms
- Track 5-3Ultrastructural considerations,induction mechanisms, methodology, kinetics of inhibition
- Track 5-4Activation, steroid and amine metabolism.
- Track 5-5NS3, the protease of flaviviruses such as dengue and West Nile virus
- Track 5-6Combined phenotypic/target-oriented screening approaches, and their application on anti-infective drug discovery
- Track 5-7Targeting of host factors involved in virus replication
- Track 5-8Targeting of host factors involved in virus replication
- Track 6-1DNA Structure
- Track 6-2Gene Cloning - Propagation of Genetic Material in Alternative Host Systems
- Track 6-3Expression of Cloned Genes
- Track 6-4Uses of Cloned Human Proteins
- Track 7-1Personalized Medicine
- Track 7-2Naturopathy and Acupuncture as a secondary medical system
- Track 7-3Drug resistance by misuse of medications
- Track 7-4Modernising Traditions
- Track 7-5Protection and piracy
- Track 8-1Plant-pathogen interactions
- Track 8-2DNA microarrays
- Track 8-3Advances in plant Tissue culture and revolutionizing agriculture
- Track 8-4Plant biotech for agriculture Improvement
- Track 9-1Can only drug cure a disease?
- Track 9-2Antioxidants
- Track 9-3Why are pharmaceuticals around?
- Track 9-4Nutraceutical Supplements as convenient and effective
- Track 9-5Bridging the gap between food and medicine
- Track 10-1Peptides with dual Antimicrobial and anticancer activities
- Track 10-2Anticancer activitiy of maize Bioactive peptides
- Track 10-3Contemporary materials safety
- Track 10-4A brief description on how EDTA is measured in blood
- Track 11-1Ligand and structure based drug design
- Track 11-2Computational Chemistry
- Track 11-3Molecular modelling
- Track 11-4Enzyme as target
- Track 11-5Receptor as target
- Track 11-6QSAR/QSPR Quantitative structure activity/property relationships
- Track 12-1ADME (adsorption,distribution,metabolism and excretion) of drugs
- Track 12-2Metabolism and toxicology
- Track 12-3Antiviral and antimicrobial activity
- Track 12-4Drug receptor interaction
- Track 12-5Kojic acid as a tyrosine inhibitor
- Track 13-1 GC-MS
- Track 13-2LC-ITIR
- Track 13-3LC-NMR
- Track 13-4Chemical fingerprinting and quality control
- Track 14-1Magnetoelectric nanoparticles
- Track 14-2Nanoparticle drug delivery
- Track 14-3Problems of multidrug resistance in cancer therapies
- Track 14-4Taxoids as potent cytotoxic agents for tumour targeting drug delivery
- Track 15-1Dementias responsible for greatest burden of neurodegenerative diseases
- Track 15-2Causes and treatments
- Track 15-3Motor neurone diseases
- Track 15-4Huntington’s disease.
- Track 16-1A pattern of depressed resistancein autism
- Track 16-2Do vaccines for children cause autism?
- Track 16-3Research supports vaccinating
- Track 16-4Autism genetic risk factors
- Track 16-5Autism environmental risk factors
- Track 17-1Determinants of Infectious diseases
- Track 17-2Emergence and Reemergence of infectious diseases
- Track 17-3HIV/AIDS:Newly emerging infectious diseases
- Track 17-4Research on emerging Infectious diseases
- Track 17-5Preventing emerging infectious diseases:A strategy for the 21st century
- Track 17-6Zika virus
- Track 18-1How do antibiotics work?
- Track 18-2What are the side effects?
- Track 18-3Main types of antibiotics
- Track 18-4Biological antibiotics derived from molds
- Track 18-5Synthetic antibiotics derived from dyes
- Track 19-1Personalized medicines: A decade of advancements
- Track 19-2Cancer genomics
- Track 19-3Pharmacogenomics
- Track 19-4Good for patients but bad for drug companies
- Track 19-5Ramifications of illicit drug markets in society
- Track 20-1Chemotherapeutic agents
- Track 20-2Microorganisms that produce antibiotics
- Track 20-3Antimicrobial peptides: Promising compounds against pathogenic microorganisms
- Track 20-4Discovery of penicillin
- Track 20-5Discovery of sulphonamides
- Track 22-1Binding kinetics and pathways of ligands to GPCRs
- Track 22-2• Aurora A kinase ,a priority pharmaceutical target for treatment of cancer
- Track 22-3Novel adjuvants designed for improving vaccine efficacy
- Track 23-1Role of computational biology
- Track 23-2Pioneering digital health and smart drug delivery systems
- Track 23-3Ligand binding studies
- Track 23-4Phage display technology for clinical application of protein drugs
- Track 24-1Potential use of stem cells for regeneration
- Track 24-2Harnessing yeast organelles for metabolic engineering
- Track 24-3Si-RNA a tool in chemical biology
- Track 24-4Discovery of biomolecules through metagenomics
- Track 24-5Protomics
- Track 25-1High throughput screening
- Track 25-2Target identification
- Track 25-3Target validation
- Track 25-4Screening cascade-Lead optimization
- Track 26-1Application of integrated data from the physical and biological sciences to problems of chemotherapy
- Track 26-2Transport of drugs to site of action
- Track 26-3Biotransformation of drugs
- Track 26-4Interaction of drugs with enzyme systems
- Track 26-5Recent advances in drug design
- Track 27-1New Drugs to Eliminate Malaria
- Track 27-2New Strategy for the Discovery of Drugs
- Track 27-3New Drug Discovery Technique to Target a Class of Enzymes
- Track 27-4 Serelaxin - Breakthrough Therapy in the Treatment of Heart Failure
- Track 27-5Discovery of Ebola Protein could Lead to Drug Development
- Track 27-6New Drug could Treat Most Aggressive Form of Lung Cancer
- Track 27-7Medicinal chemistry of drugs used in diabetic cardiomyopathy.
- Track 28-1 Advantages of fluorine in drug development
- Track 28-2Fluorinated drugs in the treatment of cardiovascular diseases
- Track 28-3Fluorinated drugs in the treatment of cardiovascular diseases
- Track 28-4Fluorinated antibacterial agents
- Track 28-5Fluorinated azole antifungal agents
- Track 28-6Fluorinated anti-inflammatory agents
- Track 28-7Fluorinated anticancer agents
- Track 29-1Mechanisms of action
- Track 29-2spectrum of coverage, resistance patterns
- Track 29-3chemical and biologic properties of agents used to prevent or treat infectious diseases
- Track 30-1Therapeutic antibodies, and drug targets
- Track 30-2Protein-protein-interactions and Protein-lipid interactions
- Track 30-3Thermodynamics and kinetics of protein-ligand interactions
- Track 31-1Integrates aspects of medicinal chemistry and pharmacokinetics with the physiology,
- Track 31-2Include ion channels and enzymes relevant to cardiovascular disease
- Track 32-1Biological Mass Spectrometry
- Track 32-2Modern ionization methods and mass analyzers
- Track 32-3Small molecule structure assignment
- Track 32-4• Quantitative assay development by LC-MS and metabolomics quantitative discovery-
- Track 34-1Design and synthesis of target compounds: thiazoles, thiophenes, benzimidazoles and boronic acid derivatives as anticancer and anti-diabetic agents.
- Track 34-2Synthesis of neuroprotective and multi target directed ligand molecules and their pharmacokinetic/pharmacodynamic (PK/PD) studies.
- Track 34-3Ionic liquid mediated C-C and C=C bond forming reactions.
- Track 34-4Re purposing of existing drug molecules for improved PK/PD profiling by modification of non pharmacophoric parts.
- Track 35-1Monoclonal antibodies
- Track 35-2Oncolytic virus therapy
- Track 35-3Cancer vaccines
- Track 36-1Lead selection from HTS and virtual screening
- Track 36-2General design principles
- Track 36-3 Drug design with defined target structure
- Track 37-1High resolution-mass spectrometry (HR-MS) technology
- Track 37-2Data-mining tools
- Track 37-3AB SCIEX TripleTOFâ„¢ 5600 System for the study of drug metabolism in BDC rats and CYP inhibition cocktail assays.
- Track 38-1Histone deacetylases (HDACs) and histone acetylases (HATs
- Track 38-2Leukaemia-associated fusion proteins
- Track 38-3Leukaemia-associated fusion proteins
- Track 39-1 Nanoparticles that deliver three anti-cancer drugs to the lymph nodes
- Track 39-2 Sustained drug delivery using a hydrogen
- Track 39-3 Photosensitizing agent to enhance the ability of drug carrying nanoparticles
- Track 39-4Nanotechnology in Drug Delivery - Heart Disease
- Track 39-5 Carbon nanofibers penetrate diseased cells
- Track 39-6Nanotechnology in Drug Delivery - Aging and other areas
- Track 40-1Pharmacokinetics
- Track 40-2Toxicology
- Track 40-3Posology
- Track 41-1Anaesthetic vaporizer
- Track 41-2Tinctures‎
- Track 41-3Transdermal patches‎
- Track 42-1Survey of major drug classes with emphasis on molecular mechanisms of action
- Track 42-2Survey of methods used in contemporary pharmaceutical research including computational and combinatorial approaches
- Track 43-1Platinum based anticancer drugs
- Track 43-2Objectives of TDDS
- Track 43-3Bioligand and its attachement to protein target